Anadys culls staff and clinical programmes
This article was originally published in Scrip
Executive Summary
Anadys Pharmaceuticals will cut 40% of its staff and halt development on two thirds of its clinical pipeline as the US firm seeks additional cash from investors. The restructuring will save Anadys around $4-5 million annually at the cost of approximately 20 jobs.